BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 31, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Aerosolized Alpha-1 antitrypsin: Phase II started

Kamada began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 80 or 160 mg inhaled AAT twice daily for 12 weeks in 36 patients. Patients will be eligible to enroll in a 12-week, open-label extension study. The product, which uses the eFlow...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >